Education
About Us
Working with TipRanks
Follow Us
MaaT Pharma (FR:MAAT)
:MAAT
Total Valuation
MaaT Pharma has a market cap or net worth of €84.30M. The enterprise value is ―.
Market Cap€84.30M
Enterprise Value―
Share Statistics
MaaT Pharma has 16,115,252 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,115,252
Owned by Insiders―
Owned by Institutions1.03%
Financial Efficiency
MaaT Pharma’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee37.76K
Profits Per Employee-334.19K
Employee Count59
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of MaaT Pharma is ―. MaaT Pharma’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, MaaT Pharma had revenue of 2.23M and earned -19.72M in profits. Earnings per share was -1.73.
Revenue2.23M
Gross Profit1.66M
Operating Income-19.94M
Pretax Income-19.72M
Net Income-19.72M
EBITDA-19.74M
Earnings Per Share (EPS)-1.73
Cash Flow
In the last 12 months, operating cash flow was -21.00M and capital expenditures -1.05M, giving a free cash flow of -22.05M billion.
Operating Cash Flow-21.00M
Free Cash Flow-22.05M
Free Cash Flow per Share-1.37
Dividends & Yields
MaaT Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.52
52-Week Price Change-35.15%
50-Day Moving Average5.22
200-Day Moving Average6.72
Relative Strength Index (RSI)53.49
Average Volume (3m)10.71K
Important Dates
MaaT Pharma upcoming earnings date is Sep 16, 2025, Before Open (Confirmed).
Last Earnings DateMar 27, 2025
Next Earnings DateSep 16, 2025
Ex-Dividend Date―
Financial Position
MaaT Pharma as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, MaaT Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
MaaT Pharma EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
MaaT Pharma has €31.15M in cash and marketable securities with €17.17M in debt, giving a net cash position of -€13.98M billion.
Cash & Marketable Securities€31.15M
Total Debt€17.17M
Net Cash-€13.98M
Net Cash Per Share-€0.87
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for MaaT Pharma is €19.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€19.00
Price Target Upside262.60% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast44.34%
EPS Growth Forecast-27.37%